Skip to main content
OpenTrials
Completed

NCT Number: NCT05553067

Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms

Detection of the potential oncogenic role of Engrailed-2 in epithelial ovarian neoplasms, in order to detect biological markers that could be targeted and blocked by new medications.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Epithelial ovarian carcinomas represent more than 90% of all ovarian carcinomas. Treatment of these ovarian carcinomas on basis of their histopathological features didn't improve patients' outcomes with very high incidence of relapses and resistance to therapy. Detection of novel biological markers which are involved in tumor progression could have promising results if these biological molecules are targeted and blocked by new medications.

Engrailed-2 is a protein encoded by a gene located on chromosome 7. Engrailed-2 is involved in neural development and neural connections during embryological life. it has been proved that Engrailed-2 is expressed in non neural neoplasms, especially in prostatic and urinary bladder carcinomas. Now estimatiion of urinary and serum levels of Engrailed-2 is used as a non-invasive screening tool in to detect prostatic and urinary bladder carcinomas. We aim to evaluated immunohistochemical expression of Engrailed-2 in normal and neoplastic ovarian tissues and to compare such expression between normal and neoplastic tissues in order to improve its oncogenic role in ovarian carcinoma.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All types of epithelial ovarian neoplasms (benign, borderline and malignant).

Exclusion criteria

  • Non-epithelial and/ or secondary ovarian tumors.
  • Cases with poor clinical data.
  • Cases who had history of pre-operative chemotherapy.

Treatment and study plan

Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.

Genetic

Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.

Primary outcomes

  1. compare levels of Engrailed-2 expression in different ovarian specimens.

    Time frame: December, 2021

    compare levels of immunohistochemical expression of Engrailed-2 in normal and neoplastic ovarian tissues. and correlate Engrailed-2 expression in neoplastic ovarian tissues to patients' ages, tumor phenotype and state of nodal metastasis.

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms.

Important dates

Study start
2015
Primary completion
2021
Study completion
2022
First posted
Sep 23, 2022
Registry last updated
Sep 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.